Contrasting gray and white matter changes in preclinical Huntington disease: An MRI study

Neurology

Volumn 74, Issue 15, 2010, Pages 1208-1216

  Stoffers, D ^a   Sheldon, S ^a   Kuperman, J M ^a   Goldstein, J ^a   Corey Bloom, J ^a   Aron, A R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

ADULT; ARTICLE; AUTOMATION; BASAL GANGLION; BRAIN REGION; BRAIN SIZE; CLINICAL ARTICLE; CONTROLLED STUDY; DEMYELINATION; DIFFUSION WEIGHTED IMAGING; FEMALE; GRAY MATTER; HUMAN; HUNTINGTON CHOREA; MALE; MORPHOMETRICS; NERVE FIBER DEGENERATION; NEUROPROTECTION; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; THALAMOCORTICAL TRACT; WHITE MATTER;

EID: 77950935234     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181d8c20a     Document Type: Article

References (40)

1. Aylward EH, Sparks BF, Field KM, et al. Onset and rate of striatal atrophy in preclinical Huntington disease. Neurology 2004;63:66-72.
2. Beal MF, Ferrante RJ. Experimental therapeutics in trans-genic mouse models of Huntington's disease. Nat Rev Neurosci 2004;5:373-384.
3. Hersch SM, Rosas HD. Neuroprotection for Hunting-ton's disease: ready, set, slow. Neurotherapeutics 2008;5: 226-236.
4. Bohanna I, Georgiou-Karistianis N, Hannan AJ, Egan GF. Magnetic resonance imaging as an approach towards identifying neuropathological biomarkers for Huntington's disease. Brain Res Rev 2008;58:209-225.
5. Aylward EH, Brandt J, Codori AM, et al. Reduced basal ganglia volume associated with the gene for Huntington's disease in asymptomatic at-risk persons. Neurology 1994; 44:823-828.
6. Aylward EH, Codori AM, Barta PE, et al. Basal ganglia volume and proximity to onset in presymptomatic Hun-tington disease. Arch Neurol 1996;53:1293-1296.
7. Aylward EH, Codori AM, Rosenblatt A, et al. Rate of caudate atrophy in presymptomatic and symptomatic stages of Huntington's disease. Mov Disord 2000;15:552-560.
8. Campodonico JR, Aylward E, Codori AM, et al. When does Huntington's disease begin? J Int Neuropsychol Soc 1998;4:467-473.
9. Harris GJ, Codori AM, Lewis RF, et al. Reduced basal ganglia blood flow and volume in pre-symptomatic, gene-tested persons at-risk for Huntington's disease. Brain 1999;122:1667-1678.
10. Kipps CM, Duggins AJ, Mahant N, et al. Progression of structural neuropathology in preclinical Huntington's disease: a tensor based morphometry study. J Neurol Neuro-surg Psychiatry 2005;76:650-655.
11. Kloppel S, Draganski B, Golding CV, et al. White matter connections reflect changes in voluntary-guided saccades in pre-symptomatic Huntington's disease. Brain 2008; 131:196-204.
12. Nopoulos P, Magnotta VA, Mikos A, et al. Morphology of the cerebral cortex in preclinical Huntington's disease. Am J Psychiatry 2007;164:1428-1434. (Pubitemid 47461144)
13. Paulsen JS, Hayden M, Stout JC, et al. Preparing for preventive clinical trials: the Predict-HD study. Arch Neurol 2006;63:883-890.
14. Paulsen JS, Magnotta VA, Mikos AE, et al. Brain structure in preclinical Huntington's disease. Biol Psychiatry 2006; 59:57-63.
15. Reading SA, Yassa MA, Bakker A, et al. Regional white matter change in pre-symptomatic Huntington's disease: a diffusion tensor imaging study. Psychiatry Res 2005;140: 55-62.
16. Rosas HD, Tuch DS, Hevelone ND, et al. Diffusion tensor imaging in presymptomatic and early Huntington's disease: selective white matter pathology and its relationship to clinical measures. Mov Disord 2006;21:1317-1325.
17. Thieben MJ, Duggins AJ, Good CD, et al. The distribution of structural neuropathology in pre-clinical Hunting-ton's disease. Brain 2002;125:1815-1828.
18. Mascalchi M, Lolli F, Della Nave R, et al. Huntington disease: volumetric, diffusion-weighted, and magnetization transfer MR imaging of brain. Radiology 2004;232:867-873.
19. Weaver KE, Richards TL, Liang O, et al. Longitudinal diffusion tensor imaging in Huntington's disease. Exp Neurol 2009;216:525-529.
20. Alexander GE, DeLong MR, Strick PL. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu Rev Neurosci 1986;9:357-381.
21. Langbehn DR, Brinkman RR, Falush D, Paulsen JS, Hay-den MR. A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length. Clin Genet 2004;65:267-277.
22. Jovicich J, Czanner S, Greve D, et al. Reliability in multi-site structural MRI studies: effects of gradient non-linearity correction on phantom and human data. Neuroimage 2006;30:436-443.
23. Hagler DJ, Jr., Ahmadi ME, Kuperman J, et al. Automated white-matter tractography using a probabilistic diffusion tensor atlas: application to temporal lobe epilepsy. Hum Brain Mapp 2008;30:1535-1547.
24. Smith SM, Jenkinson M, Woolrich MW, et al. Advances in functional and structural MR image analysis and implementation as FSL. Neuroimage 2004;23:S208-S219.
25. Smith SM, De Stefano N, Jenkinson M, Matthews PM. Normalized accurate measurement of longitudinal brain change. J Comput Assist Tomogr 2001;25:466-475.
26. Smith SM, Zhang Y, Jenkinson M, et al. Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. Neuroimage 2002;17:479-489.
27. Ashburner J, Friston KJ. Voxel-based morphometry: the methods. Neuroimage 2000;11:805-821.
28. Smith SM, Jenkinson M, Johansen-Berg H, et al. Tract-based spatial statistics: voxelwise analysis of multi-subject diffusion data. Neuroimage 2006;31:1487-1505.
29. Nichols TE, Holmes AP. Nonparametric permutation tests for functional neuroimaging: a primer with examples. Hum Brain Mapp 2002;15:1-25.
30. Smith SM, Nichols TE. Threshold-free cluster enhancement: addressing problems of smoothing, threshold dependence and localisation in cluster inference. Neuroimage 2009;44:83-98.
31. Huntington Study Group. Unified Huntington's Disease Rating Scale: reliability and consistency. Mov Disord 1996;11:136-142.
32. Sormani MP, Rovaris M, Valsasina P, et al. Measurement error of two different techniques for brain atrophy assessment in multiple sclerosis. Neurology 2004;62:1432-1434.
33. Ashburner J, Friston KJ. Why voxel-based morphometry should be used. Neuroimage 2001;14:1238-1243.
34. Bookstein FL. "Voxel-based morphometry" should not be used with imperfectly registered images. Neuroimage 2001;14:1454-1462.
35. Stoffers D, Kuperman J, Sheldon S, et al. Automated segmentation shows atrophy of striatum and pallidum in pre-clinical HD, which strongly predict estimated years to onset. Movement Disorders Society 13th International Congress; Paris; 2009.
36. Beaulieu C. The basis of anisotropic water diffusion in the nervous system: a technical review. NMR Biomed 2002; 15:435-455.
37. Song SK, Sun SW, Ramsbottom MJ, et al. Dysmyelina-tion revealed through MRI as increased radial (but unchanged axial) diffusion of water. Neuroimage 2002;17: 1429-1436.
38. Concha L, Gross DW, Wheatley BM, Beaulieu C. Diffusion tensor imaging of time-dependent axonal and myelin degradation after corpus callosotomy in epilepsy patients. Neuroimage 2006;32:1090-1099.
39. Gomez-Tortosa E, MacDonald ME, Friend JC, et al. Quantitative neuropathological changes in presymptom-atic Huntington's disease. Ann Neurol 2001;49:29-34.
40. Bartzokis G, Lu PH, Tishler TA, et al. Myelin breakdown and iron changes in Huntington's disease: pathogenesis and treatment implications. Neurochem Res 2007;32:1655-1664.